Arginina descarboxilada, Agmatina
La agmatina es un compuesto sintetizado a partir del aminoácido arginina por la enzima arginina descarboxilasa. La suplementación se produce en forma de sulfato de agmatina. El sulfato de agmatina es absorbido en el tracto gastrointestinal y luego se distribuye rápidamente por todo el cuerpo, incluido el cerebro. Así, el sulfato de agmatina se puede utilizar en un amplio abanico de afecciones, desde el tratamiento de la diabetes, neuropatías, enfermedades neurodegenerativas y trastornos conductuales y cognitivos, incluso para mejorar el rendimiento deportivo, ya que tiene un efecto vasodilatador, permitiendo un adecuado aporte de nutrientes al tejido muscular y favoreciendo la hipertrofia.
- Origen: Sintético, producto animal, a base de plantas
- Fuente: Sintético, Vino, Cerveza, Pescado, Carne, el Sake, Café
- Tipo: Aminoácido
- Rango de edad: Adults (18-60)
- Toxicidad: Hasta ahora no hay evidencia de su toxicidad.
- Outcomes: Energía y Estado de Ánimo, Depresión
What are Agmatina benefits?
Es un metabolito del aminoácido arginina. Descubierto en 1910 por el premio Nobel Albrecht Kossel, es absorbido por el intestino y distribuido por todo el cuerpo, incluido el sistema nervioso. En estudios realizados con agmatina, se ha demostrado una reducción del dolor. El resultado indicó una disminución del dolor incluso después de la suplementación. En otros estudios la depresión se redujo drásticamente con 2-3 g de suplementos de agmatina en voluntarios. Como su mayor beneficio es el humor, su uso se ha hecho conocido entre personas con depresión y / o ansiedad. ¡A través de nuestros 3 pasos podrás comprobar la acción de este nutracéutico en tu salud de forma personalizada!
Table of relations
Published articles about Agmatine and Depresión
Efectos de la suplementación con zinc sobre la eficacia de la terapia con antidepresivos, las citoquinas inflamatorias y el factor neurotrófico derivado del cerebro en pacientes con depresión mayor
The addition of zinc (25mg) to SSRI antidepressant therapy, when compared to SSRI therapy with placebo, was associated with a reduction of depressive symptoms as assessed by the HDRS after 12 weeks. This benefit was not associated with alteration sin IL-6. TNF-α, or BDNF relative to the SSRI-placebo group. BDNF failed to increase significantly since the placebo group experienced a similar increase.
La suplementación con zinc aumenta la eficacia de la imipramina en pacientes resistentes al tratamiento: un estudio doble, controlado con placebo
A 12 week double blind study using zinc as an add-on to Imipramine therapy concluded that 25mg elemental zinc was more effective than placebo in reducing depressive symptoms in treatment resistant persons, normalizing the difference between treatment resistant and nonresistant as assessed by BDI. Participants were not measured for zinc deficiencies.
La monoterapia con zinc aumenta los niveles neurotróficos derivados del cerebro (BDNF) suero y disminuye los síntomas depresivos en temas con sobrepeso u obesos: un ensayo doble ciego, aleatorizado y controlado con placebo
Supplementation of zinc (30mg elemental) for 12 weeks in obese persons with depressive symptoms according to the BDI II rating scale was able to improve symptoms more than placebo; this improvement in depressive symptoms occurred alongside increases in serum BDNF concentrations.
Efecto de la suplementación con zinc sobre los estados de ánimo en mujeres jóvenes: un estudio piloto
Supplementation of a control multivitamin with or without an additional 7mg of elemental zinc is associated with an improvement in mood as assessed by mostly aggressive and depressive symptoms and the overall scores on the Profile of Moods State rating scale in otherwise healthy young women.
Efecto de la suplementación con sulfato de zinc en el síndrome premenstrual y la calidad de vida relacionada con la salud: prueba clínica controlada aleatorizada
In a randomized, double-blind, placebo-controlled trial, 142 women with PMS were allocated to either 220 mg of zinc sulfate (50 mg of elemental zinc) or placebo daily from the 16th day of each menstrual cycle to the 2nd day of the next for 3 months. On the Premenstrual Symptoms Screening Tool, anger/irritability, anxiety/tension, depressed mood, decreased interest in world activities, decreased interest in-home activities, difficulty concentrating, fatigue, insomnia, hypersomnia, feeling overwhelmed, and physical symptoms all improved in the zinc group more than the placebo group, the difference being statistically significant. In contrast, tearfulness wasn't improved. The improvement in work efficiency, relationship with coworkers, relationships with family, social life activities, and home responsibilities were all improved more in the zinc group than the placebo group, the difference being statistically significant. The improvement tended to increase each month, which likely reflects zinc status improving each month. On the 12-item Short-Form Health Survey Questionnaire, there was a modest improvement for both physical and psychological symptoms which was statistically significant compared with placebo.
Evaluación de los efectos de la vitamina D y el suplemento de vitamina E en el síndrome premenstrual: un ensayo aleatorizado, doble ciego y controlado
In a randomized, double-blind, placebo-controlled trial, 28 women with premenstrual syndrome were allocated to take 200 mg of vitamin D or placebo daily for 2 months. There was a slightly greater improvement in overall symptoms in the vitamin D group, but the difference between groups wasn't statistically significant. The depression score saw a more notable improvement compared with the others, though it's unclear if the difference was statistically significant.
La suplementación con vitamina D afecta el inventario de la depresión de Beck, la resistencia a la insulina y los biomarcadores de estrés oxidativo en pacientes con trastorno depresivo mayor: un ensayo clínico controlado aleatorizado
In a randomized, double-blinded and placebo-controlled clinical trial high-dose vitamin D supplementation was shown to reduce depressive symptoms and improver markers for glucose homeostasis in individuals with major depressive disorder (MDD).
S-Adenosyl metionina (la misma) versus escitalopram y placebo en la depresión mayor ECC: eficacia y efectos de la histamina y la carnitina como moderadores de respuesta
Effect size from baseline to endpoint was moderate to large for SAMe versus placebo (d=0.74). SAMe was superior to escitalopram during weeks 2-6 but not 8-12, as escitalopram response was slow but caught up with SAMe late in the trial. Final response rates (HAMD-17≥50% reduction) were 45%, 31%, and 26% for SAMe, escitalopram, and placebo, respectively. Remission rates (HAM-D≤7) were 34% for SAMe (p=0.003), 23% for escitalopram (p=0.023), and 6% for placebo.
S-Adenosyl metionina (mismo) Aumento de los inhibidores de la recaptación de serotonina para los no respuestas antidepresivos con trastorno depresivo mayor: un ensayo clínico doble ciego y aleatorizado
SAMe was able to augment the efficacy of SSRI therapy in 79 persons using SSRI medication without significantly influencing side-effects or drop-out rate due to inefficacy at 1600mg daily for 6 weeks
S-Adenosyl-metionina mejora la depresión en pacientes con enfermedad de Parkinson en un ensayo clínico de etiqueta abierta
Depression associated with Parkinson's Disease is attenuated with 800-3600mg SAMe for 10 weeks by up to 65%; unblinded study with placebo as confounder
Eficacia y seguridad de la suplementación oral de magnesio en el tratamiento de la depresión en los ancianos con diabetes tipo 2: un ensayo aleatorizado y equivalente
450mg magnesium was equally effective as 50mg imipramine for attenuating depressive symptoms in elderly, magnesium deficiency, persons with type II diabetes
In a randomized, double-blind, placebo-controlled trial, 126 women with premenstrual syndrome were allocated to take 250 mg of magnesium from magnesium oxide, vitamin B6, or placebo daily for 4 months. At the end of the 4 months, there was a reduction in mean symptoms in all groups but were reduced somewhat more in the magnesium and vitamin B6 groups, which was statistically significant compared with the placebo group. This was derived from cravings, depression, water retention, anxiety, and somatic changes on the Abraham's classification.
El efecto antidepresivo clínico de la agmatina exógena no se invierte por la paraclorofenilalanina: un estudio piloto
Oral ingestion of 2-3 g agmatine over 6-8 weeks in three subjects who were diagnosed with either major depressive disorder or unipolar depression, who were not on any pharmaceuticals nor did they have treatment-resistant depression, was able to induce remission of depressive symptoms in all subjects.
Fluoxetine versus Vitex Agnus Bastus Extracto en el tratamiento del trastorno disfórico premenstrual
In a randomized, single-blind comparator trial, 41 women with premenstrual dysphoric disorder were allocated to take 20-40 mg of fluoxetine or 20-40 mg of Vitex agnus castus (with flexible dosing) for 2 months. Scores on the Penn daily symptom scale, the Hamilton Depression Scale, and global impression-severity of illness improved notably in both groups, with no differences between groups.
Evaluación del efecto terapéutico en los síntomas del síndrome premenstrual moderado a severo con Vitex Agnus Castus (BNO 1095) en mujeres chinas
4mg of BNO 1095 (10:1 concentrated ethanolic extract of the plant) daily appears to reduce a variety of symptoms in Chinese women suffering moderate to severe PMS symptoms when taken daily.
4.5mg (40 drops) of Vitex Agnus taken 6 days prior to menstruation and continued for 3 months was associated with improved symptoms of PMS relative to placebo.
Over the course of six menstrual cycles, supplementation with 12g inositol or its gel form equivalent (3.6g) were both effective in reducing dysphoria and depression associated with PMS.
Supplementation of 12g inositol daily for a period of four weeks to depressed persons was associated with significant improvements in depressive symptoms. Treatment was well tolerated.
Supplementation of 12g inositol over the course of four weeks in persons who were nonresponsive to 3 weeks of SSRI therapy failed to outperform placebo in reducing depressive symptoms.
Supplementation of 6g inositol to treatment resistant depressed persons was able to improve depressive symptoms in 9/11 persons (open-label trial) and a subsequent double-blind trial in schizophrenic persons failed to find any apparent benefit over 30 days with the same dose. Liver and kidney function was unaffected.
Eficacia de la curcumina y una combinación de azafrán / curcumina para el tratamiento de la depresión mayor: un estudio aleatorizado, doble ciego, controlado con placebo
This was a 12-week randomized, double-blind, placebo-controlled trial on males and females 18-65 years of age who met the DSM-IV criteria for major depressive disorder and who had an Inventory of Depressive Symptomatology self-rated version (IDS-SR30) score of at least 18. The primary outcome measures were the IDS-SR30 scores and the secondary outcomes were STAI-T and STAI-S scores. The participants were randomized to four groups: The remaining participants were randomized to four groups with the following capsules: placebo, low-dose curcumin containing 250 milligrams of the patented curcumin BCM-95 (LDC), high-dose curcumin containing 500 milligrams of BCM-95 (HDC), and low-dose curcumin/ saffron combination, containing 250 milligrams of BCM-95 and 15 milligrams of a saffron extract(LDC+S). After 12 weeks, the combined curcumin group experienced a 33.1% reduction in IDS-SR30 scores, a 19.0% reduction in STAI-S scores, and a 16.5% reduction in STAI-T scores.
El tratamiento adicional con curcumina tiene efectos antidepresivos en pacientes tailandeses con depresión mayor: resultados de un estudio controlado por placebo doble ciego aleatorio
In a randomized, double-blind, placebo-controlled trial, 65 participants with major depression who were taking antidepressants were assigned to take a curcuminoid supplement or placebo for 12 weeks. The curcuminoid supplement contained 77% curcumin, 17% demethoxycurcumin, and 6% bisdemethoxycurcumin. For the first week, participants took 500 mg and increased their dose by 250 mg each week until at week 4, they were taking 1,500 mg daily which they continued for the rest of the trial. The primary outcome was depression as evaluated by the Montgomery–Åsberg Depression Rating Scale (MADRS). MADRS score declined substantially for both groups, with a notable, statistically significant improvement in the curcuminoid group compared with the placebo group at week 12, which continued for at least 4 weeks after discontinuing supplementation. However, this effect was only found in males, and not females. The secondary outcome was anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A). In males, a modest reduction was found compared with placebo. However, the reduction was smaller in the placebo group for females, though there wasn't strong evidence for effects of sex. There were no adverse events associated with curcumin, and none of the blood tests showed worrying trends.
La suplementación crónica de la curcumina mejora la eficacia de los antidepresivos en un trastorno depresivo mayor: un estudio piloto aleatorizado, doble ciego, controlado con placebo controlado con placebo
In a randomized, double-blind, placebo-controlled pilot study, 108 male participants with major depression were assigned to take placebo or 1,000 mg of curcuminoids (>95% purity) for 6 weeks. All participants were also given escitalopram. The curcumin group saw a modestly greater reduction in depression as measured by the Hamilton Depression Rating Scale and the Montgomery–Åsberg Depression Rating Scale, both of which were statistically significant compared with placebo. The percentage of participants achieving at least a 50% reduction in their score was higher in the curcumin group as well. The curcumin group saw a greater reduction in IL-1β, TNF-α, and salivary cortisol, and an increase in BDNF levels, all of which were statistically significant compared with the placebo group.
Investigación de la eficacia de la terapia complementaria con biodisponibilidad: curcuminoides impulsados en un trastorno depresivo mayor
In an open-label trial, 111 participants with major depression were assigned to take standard antidepressant therapy or antidepressants with 1000 mg of curcuminoids and 10 mg piperine daily for 6 weeks. By the end of the trial, 26% of participants had dropped out of the trial, with a somewhat higher rate in the curcuminoid group. The participants were measured for symptoms of depression and anxiety by the Beck-II inventory and the Hospital Anxiety and Depression Scale (HADS). For Beck-II, the reduction in depression was modestly larger for curcuminoids than for placebo and statistically significant in comparison. The same was the case for HADS for both anxiety and depression.
Supplementation of 12g inositol daily for a period of six weeks in persons with bipolar disorder and depression was associated with a trend towards reducing symptoms of bipolar disorder and depressive symptoms, but this was not statistically significant.
Depresión bipolar resistente al tratamiento: un ensayo de eficacia aleatorizado de Equipo de Paso BD de aumento de antidepresivos con lamotrigina, inositol o risperidona
In an open-label trial, depressive symptoms of bipolar disorder were significantly reduced in response to inositol supplementation over six weeks. No placebo control was used in this study.
Curcumina para el tratamiento de la depresión mayor: un estudio aleatorizado, doble ciego, controlado con placebo
A total of 56 individuals with MDD were treated with 500 mg of BCM-95 curcumin (twice daily) or placebo for eight weeks. The primary measure was the IDS-SR30. Secondary outcomes included IDS-SR30 factor scores and the STAI. After eight weeks, The curcumin group experienced a 33.1% decrease in IDS-SR30 scores, a 19% decrease in STAI-S scores and a 14.8% decrease in STAI-T scores.
Eficacia y seguridad de la curcumina en el trastorno depresivo mayor: un ensayo controlado aleatorio
A trial using 500mg twice daily (total daily dose of 1g, 88% curcuminoids) relative to 20mg fluoxetine but no placebo control in persons with major depressive disorder noted that the reduction in symptoms as assessed by the HAM-D rating scale with curcumin (62.5%) was similar to that seen with fluoxetine (64.7%) and combination of the two (77.8%; difference not significant) while remission rates were similar between all groups. No significant side effects were reported, although mild side effects were similar with both monotherapies and trended to be more frequent in the combination group.
Una investigación de los efectos de la curcumina sobre la ansiedad y la depresión en individuos obesos: un ensayo controlado aleatorizado
Thirty-five subjects (mean age: 38.37 ±11.51; 83% females were a part of the trial. Participants were given either capsules containing a mix of 500 mg of C3 Complex, along with 5 mg of bioperine or placebo capsules that were of the exact size and shape, which only contained 5 mg of bioperine. The subjects were required to take two capsules of curcumin a day (1 g) or two capsules of placebo a day for thirty days. The treatment period lasted for thirty days after which the patients were required to switch over to the alternative treatment following a 2-week wash-out interval between the regimens. Psychometric tests such as the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) were administered to each participant at baseline, week 4, 6, and 10 of the trial. The trial found that curcumin had no significant effect on the mean BDI score for the overall study population when compared to placebo (P=0.7), however, it was associated with a significant reduction on the mean BAI score when compared to the placebo group (P=0.03).
Curcumina como un complemento a tratamiento antidepresivo: un estudio clínico piloto aleatorizado, doble ciego, controlado con placebo, controlado con placebo
This was a 5-week randomized, double-blind, placebo-controlled, study that recruited 40 males and females aged 20-60 years who were diagnosed with major depressive disorder. The participants were already taking antidepressant medication and were randomized to one of two groups: a placebo group, or a group that was required to take a daily capsule consisting of 330 mg of curcumin (97% concentrate), 120 mg of ellagic acid (70% concentrate) extracted from pomegranate’s peel, and 50 mg of piperine (the active ingredient in black pepper). The primary outcomes were the HDRS, MADRS, and CGI-S. The overall differences between the two groups were not statistically significant with regards to a decrease in symptoms of depression. In the placebo group, the MADRS scores decreased by a mean of 5.3 points (95% confidence interval [CI], 2.1–8.5; P < 0.01); whereas in the curcumin group, the scores decreased by a mean of 10.4 points (95% CI, 7.2–13.7; P < 0.001). The HDRS scores in the placebo group diminished by a mean of 5.1 points (95% CI, 2.0–8.1; P < 0.01), and those in the curcumin group diminished by a means of 8.0 points (95% CI, 4.8–11.1; P < 0.001). The CGI-S scores in the placebo group diminished by a mean of 0.6 points (95% CI, 0.2–0.9; P < 0.01), and those in the curcumin group diminished by a mean of 0.7 points (95% CI, 0.4–1.1; P < 0.001).
In a placebo controlled crossover design, supplementation of 18g inositol daily for six weeks in persons with obsessive compulsive disorder was able to reduce symptoms as assessed by the Yale-Brown Obsessive Compulsive Scale (to 76% of baseline; placebo down to 94%)
El extracto de Kava-Kava WS 1490 versus placebo en trastornos de ansiedad: un ensayo para pacientes ambulatorios controlados por placebo aleatorios
101 patients suffering from non-psychotic anxiety using Kava (WS 1490 extract) over 25 weeks noted statistically significant benefits starting after week 8.
El estudio del espectro de la depresión de la ansiedad de Kava (KADSS): un ensayo de cruce aleatorizado y controlado con placebo con un extracto acuoso de Piper Metsticum
Over a period of 3 weeks active treatment (one week run in phase),16g of Kava standardized to 250mg of activa kavalactones daily (2/5ths in the morning and afternoon, 1/5th in the evening) as an aqueous extract was able to exert anxiolytic and anti-depressive actions in persons with at least one month of higher but stable anxiety levels. No hepatotoxic signs noted via clinical assessment, liver enzymes not measured.
Supplementation of 18g inositol in persons with binge eating disorder or bulimia was effective in reducing symptoms of binge eating as well as both anxiety and depression. The lone male patient did not respond to treatment.
Un estudio prospectivo y aleatorizado de doble ciego, controlado con placebo de seguridad y eficacia de un extracto de espectro completo de alta concentración de raíz de ashwagandha en la reducción del estrés y la ansiedad en los adultos.
600 mg of an ashwagandha extract ('full spectrum') for 60 days in persons with chronic mental stress was able to improve all tested parameters and reduced serum cortisol by 27.9%.
Una evaluación doble ciega y controlada con placebo de la eficacia ansiolítica FF un extracto etanólico de Withania Somnifera
Six weeks supplementation of Ashwagandha (250mg twice daily of the root extract) in persons with diagnosed generalized anxiety disorder (mixed anxiety and depression) noted significant improvements in both depression and anxiety symptoms. This study had a high dropout rate (18 out of 39 persons)
Estudio complementario controlado por placebo aleatorizado de un extracto de Somnifera con la disfunción cognitiva en el trastorno bipolar
In a randomized, double-blind, placebo-controlled trial, 60 subjects with bipolar disorder took an ashwagandha extract or placebo for 8 weeks. The subjects who took ashwagandha received 250 mg/d (standardized to a minimum of 8% withanolides and a maximum of 2% Withaferin A) for the first week, and 500 mg for the rest of the study, however, if the participants suspected adverse effects of ashwagandha, they were allowed to reduce their dose to 250 mg/d, which was the case with 3. The primary outcome was working memory as evaluated by an auditory 8 Digit-Span test. Compared with placebo, the ashwagandha group saw a small, statistically significant improvement in the span backward portion, but not for span forward. The participants also performed the flanker test and the results favored the ashwagandha group but were only statistically significant for the neutral condition. Results for tests of executive function and processing speed were ambiguous and not statistically significant. The researchers also evaluated affective symptoms and possibly found reductions in depression and mania, but not anxiety, though statistical tests weren't performed for these. The only adverse event that seemed to be higher in the ashwagandha group was diarrhea in 5 participants compared with 1 in the placebo group.
La depresión es una condición psiquiátrica crónica y recurrente que produce cambios de humor caracterizados por una profunda tristeza, cambios de humor, pérdida de interés en actividades, provocando un deterioro significativo en la vida diaria.